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ABSTRACT
Drug-induced hypertension offers the opportunity to further understand pathways involved in the regulation of blood
pressure. Posaconazole is an antifungal agent known to induce hypertension and hypokalaemia. In recent months, a flurry
of reports has unravelled the metabolic processes involved. In this issue of CKJ, Barton K, Davis TK, Marshall B et al.
Posaconazole-induced hypertension and hypokalemia due to inhibition of the 11b-hydroxylase enzyme. Clin Kidney J 2018;
11: 691–693 present convincing evidence of 11b-hydroxylase inhibition resulting in a biochemical syndrome resembling
genetic congenital adrenal hyperplasia and characterized by high 11-deoxycorticosterone and 11-deoxycortisol levels as
well as androgen levels. This adds to prior evidence supporting inhibition of 11b-hydroxysteroid dehydrogenase 2, the
enzyme that inactivates cortisol in aldosterone-sensitive tissues such as the kidneys, yielding a syndrome resembling
genetic apparent mineralocorticoid excess or licorice toxicity, characterized by a high cortisol/cortisone ratio.
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Posaconazole is a triazole antifungal drug, structurally similar
to fluconazole, itraconazole and voriconazole. In Europe, it is
approved to treat invasive aspergillosis, fusariosis, chromoblas-
tomycosis, mycetoma and coccidioidomycosis, when treat-
ments with other antifungal medicines (amphotericin B,
itraconazole or fluconazole) cannot be tolerated or have failed,
and to prevent invasive fungal infections in immunocompro-
mised patients [1]. Although hypertension and hypokalaemia
are listed as common adverse effects and high blood pressure
was already noted in preclinical studies, it was not until 2017
that insights into the molecular mechanisms of posaconazole-
induced hypertension were published [2–6]. A virtual screening
of drugs inhibiting 11b-hydroxysteroid dehydrogenase 2 (11b-
HSD2, corticosteroid 11b-dehydrogenase isozyme 2), followed
by biological assessment of selected hits, identified itraconazole
[half maximal inhibitory concentration (IC50) 139614 nM] and
posaconazole (IC50 460698 nM) as potent inhibitors of human
11b-HSD2 in cell lysates, although activity against rodent 11b-
HSD2 was considerably lower [2]. The IC50 for posaconazole is
well within the maximum serum concentration (Cmax) of
around 700 nM following a single 200 mg dose [7]. Additionally,
in this issue of CKJ, Barton et al. present convincing evidence of
11b-hydroxylase inhibition in a well-characterized patient [8].
Overall, the picture that has emerged is that of dose-dependent
hypertension associated with hypokalaemia, metabolic alkalo-
sis and suppressed renin and aldosterone levels [3–6, 8], which
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has been variously described as apparent mineralocorticoid
excess (AME) [4], pseudohyperaldosteronism [6] or adrenal hy-
perplasia [8].
WHAT IS 11b-HYDROXYLASE?
11b-hydroxylase, encoded by the CYP11B1 gene, is a mitochon-
drial enzyme catalysing the addition of a hydroxyl group to
11-deoxycorticosterone and 11-deoxycortisol to yield corticoste-
rone and cortisol, respectively (Figure 1). Inactivating mutations
in CYP11B1 cause a rare form of autosomal recessive congenital
adrenal hyperplasia, characterized by aberrant sex steroid pro-
duction, leading to virilization of female newborns, and, in both
the genders, advanced bone ages and hypertension [10]. A high
11-deoxycortisol level is the most robust diagnostic biochemical
marker.
WHAT IS 11b-HSD2?
11b-HSD2, encoded by the HSD11B2 gene, oxidizes cortisol to
the inactive metabolite cortisone, thus preventing activation of
the mineralocorticoid receptor (MR) by cortisol, which circulates
at 100- to 1000-fold higher concentrations than aldosterone,
and binds with equal affinity to the MR [9]. 11b-HSD2 is mainly
expressed by aldosterone-sensitive tissues, such as the kidneys,
to prevent physiological cortisol levels from activating the MR.
At the endoplasmic reticulum membrane it functionally inter-
acts with the MR [11]. 11b-HSD2 inactivation results in physio-
logical cortisol levels fully activating MR-driven kidney
responses leading to aldosterone-independent MR activation.
Indeed, inactivating mutations cause autosomal recessive AME,
which disappears following kidney transplantation [12]. An ele-
vation in the urinary tetrahydrocortisol (THF) plus allo-THF to
tetrahydrocortisone (THE) [(THF þ allo-THF)/THE] ratio is patho-
gnomonic of homozygous inactivation, but it was reported to be
less sensitive than a high serum cortisol/cortisone ratio to
detect heterozygous subjects with milder enzyme deficiency
[13]. 11b-HSD2 is also inhibited by glycyrrhetinic acid, a metabo-
lite generated in vivo from glycyrrhizic acid present in licorice,
which causes aldosterone-independent MR activation [14]. Mild
11b-HSD2 defects have been suggested to contribute to essential
hypertension [9].
11b-HSD2 is also expressed at high level in the placenta,
where it is thought to regulate the passage of maternal active
glucocorticoids into the fetal circulation and maternal-fetal
electrolyte and water transport [12].
WHAT IS THE EVIDENCE FOR POSACONAZOLE
INHIBITION OF 11b-HSD2 AND OF 11b-
HYDROXYLASE?
Three recent reports have described a syndrome of excess MR
activation characterized by hypertension, hypokalaemia, sup-
pressed renin and aldosterone levels, and evidence of inhibition
of mitochondrial 11b-hydroxylase and, less convincingly, of
11b-HSD2 (Figure 1).
Thompson et al. observed reversible increases in 11-
deoxycortisol levels as well as a high cortisol/cortisone ratio,
that is, evidence of both 11b-hydroxylase and 11b-HSD2 inhibi-
tion, within weeks of initiating posaconazole therapy [4].
In this issue of CKJ, Barton et al. present convincing evidence of
11b-hydroxylase inhibition in a well-characterized patient [8].
Marked elevations in deoxycorticosterone, 11-deoxycortisol and
androgens were observed in the absence of mutations in HSD11B2
or CYP11B1, and these changes were reversible upon posacon-
azole withdrawal. This also answers the question whether
genetic variants in either HSD11B2 or CYP11B1 may render the
individual more sensitive to posaconazole-induced hypertension.
Unfortunately, the cortisol/cortisone ratio was not explored.
Boughton et al. observed very high 11-deoxycorticosterone and
11-deoxycortisol levels, high androstenedione levels and increased
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FIGURE 1: Human in vivo evidence of posaconazole inhibition of the mitochondrial enzyme 11b-hydroxylase and of kidney 11b-HSD2 driving aldosterone-independent
MR activation causing hypertension and hypokalaemia. Target enzymes are in red and bold, molecules (11-deoxycorticosterone, cortisol) potentially driving MR activa-
tion in patients on posaconazole are in bold and underlined. The MR-activating effect of cortisol will only be noticed in tissues dependent on 11b-HSD2 to degrade corti-
sol and prevent cortisol activation of the receptor, such as the kidney. Arrows indicate whether specific metabolites were found increased, decreased or within the
normal range (¼) by the three recent case reports, which are colour coded in dark blue [4], light blue [8] and red [5]. 11b-HSD2 is also inhibited by glycyrrhetinic acid, a
metabolite generated in vivo from glycyrrhizic acid present in licorice [9].
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serum cortisol/cortisone ratio, again suggestive of both 11b-hy-
droxylase and 11b-HSD2 inhibition [5]. They also documented bi-
lateral adrenal hyperplasia. However, they did not document the
reversibility of biochemical changes upon posaconazole with-
drawal. The patient improved on spironolactone.
WHAT IS THE EXPLANATION FOR THE
DIVERGENT FINDINGS?
A key difference between the three reports is the finding by
Thompson et al. of normal adrenocorticotropic hormone (ACTH)
and 11-deoxycorticosterone levels, in contrast to the high level
reported by Boughton and (for 11-deoxycorticosterone) by Barton
et al. [4, 5, 8]. One possibility relates to the time-course. Thompson
et al. studied their patient a few weeks into posaconazole therapy,
while the Boughton patient had been on long-term prophylactic
posaconazole and although Barton’s timing is unclear, the pro-
phylactic prescription also suggests long-time use. Longer therapy
may favour adaptive responses such as increased ACTH levels
that drive up the level of upstream molecules.
Thompson and Boughton found high serum cortisol/corti-
sone ratios suggestive of 11b-HSD2 inhibition, but only
Boughton studied urinary ratios of their metabolite, which were
normal, arguing against severe 11b-HSD2 inhibition [13].
Further studies in this regard are needed.
ARE THESE PATIENTS AT RISK OF ADRENAL
INSUFFICIENCY?
Despite normal cortisol levels, the abnormally low cortisol re-
sponse to ACTH stimulation conveys risk of suboptimal re-
sponse to stress [5]. This should be taken into account in the
care of these patients.
IS THERE A ROLE FOR CATECHOLAMINES IN
HYPERTENSION?
Barton et al. observed high catecholamine and metanephrine
levels that may or may not have been related to concurrent
medications [8]. Interestingly, 11BHSD2/ (11b-HSD2-deficient)
mice develop over time hypertension characterized by high uri-
nary catecholamine levels that is responsive to a1-adrenergic
receptor blockade [15], while high norepinephrine levels have
been reported in 11b-hydroxylase-deficient individuals [16].
Careful analysis of patients on and off posaconazole may pro-
vide further insights into the connections between cortisol
pathway enzymes and catecholamines.
CONCLUSION
In conclusion, three recent case reports addressing different
and complementary aspects of posaconazole-induced hyper-
tension with hypokalaemia converge on aldosterone-
independent MR activation and dismiss previous suggestions of
intestinal losses driving hypokalaemia. A correct understanding
of the pathogenic mechanisms avoids unnecessary diagnostic
workups in routine clinical care and offers the possibility of fur-
ther research to unravel the pathophysiology of 11b-HSD2 and
11b-hydroxylase and their connection to catecholamines, by
taking advantage of the reversible nature of posaconazole pre-
scription and of the different therapeutic and prophylactic regi-
mens in clinical use.
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